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Abstract
Background: Multidisciplinary meetings (MDM) are the current “gold standard” in interstitial lung disease (ILD)
diagnosis and comprise inter-disciplinary discussion of multiple forms of information to provide diagnostic and
management outputs. Although bias could be potentially inserted at any step in the discussion process, to date
there has been no consensus regarding the appropriate constitution and governance of MDM. We sought to
determine the features of ILD MDMs based within ILD centres of excellence around the world.
Methods: An internet based questionnaire was sent to twelve expert centres in Europe, North America, and
Australia seeking information regarding the structure and governance of their MDM. Data was analysed for
consistent themes and points of contrast.
Results: Responses were received from 10 out of 12 centres. Similarities were demonstrated with regards to
contributing attendees, meeting frequency and case numbers reviewed. Significant heterogeneity in attendee
speciality group type, quantity and method of data presentation, approach to diagnosis formulation and
documentation, and information provision was apparent.
Conclusions: The constitution of ILD MDMs differs considerably between expert centres. Such differences may
result in discordant outcomes, and emphasise the need for further evidence regarding the appropriate constitution
and governance of ILD MDMs.
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Background
Differences in clinical presentation of interstitial lung
diseases (ILD) can be subtle, yet their natural history
and response to therapy may display striking disparity
[1, 2]. For example, idiopathic pulmonary fibrosis (IPF),
a progressive and fatal subtype of idiopathic interstitial
pneumonia (IIP), displays clinical, radiological and histo-
logical features that have considerable overlap with other
subtypes. While IPF historically possesses a significantly
worse prognosis [3], anti-fibrotic therapies are now avail-
able that delay its progression [4, 5], making its accurate
identification critical. With the use of a multidisciplinary
meeting (MDM), the differentiation of IPF from other
diagnoses occurs with improved interobserver agreement
along with improved recognition of rare diseases [6]. As a
result of this, recent consensus statements regarding IPF
and ILD have advocated that a multi-disciplinary
approach be used for their diagnosis [2, 7, 8].
By definition, the MDM requires input from a variety
of specialties, but the most appropriate form of MDM
constitution and governance remains unclear. The con-
stitution of ILD MDMs may have important diagnostic
and therapeutic implications, Flaherty et al. demonstrat-
ing that academic physicians in a multidisciplinary set-
ting display better diagnostic agreement and consider a
broader range of diagnoses, compared to community
physicians [9]. The ILD MDM has potential for bias de-
pending on the expertise and number of its attendees,
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nature of clinical inputs and quality and quantity of data
provided. Such biases may have profound effects should
they lead to diagnostic error, given that resultant thera-
peutic decisions may, for example, lead to the use of
agents for indications where efficacy is not established,
or even for those where they may cause harm [10]. We
sought to determine the constitution and governance of
ILD MDMs in expert centres to provide information on
current standard of care.
Methods
Following approval by the Alfred Hospital (Melbourne,
Australia) ethics committee (project number 65/15), an
internet based questionnaire was sent to twelve expert
centres in Australia, Europe, and North America, using
SurveyMonkey™ (Palo Alto, USA). All respondents pro-
vided written informed consent for participation in the
study. Purposive sampling was performed to ensure mul-
tiple continents were included among the responders.
Within those regions, expert centres were defined as
those to which the affiliated clinician had most fre-
quently published in the field of IPF in 2014 as deter-
mined by their publication count within the US National
Library of Medicine online database. We did not differ-
entiate between ILD specific centers and larger hospitals,
nor whether there were some patients within those insti-
tutions who were not presented at the MDM. Surveyed
physicians were asked to describe their affiliated institu-
tion’s MDM using a questionnaire that included the op-
portunity for respondents to provide both prompted and
open-ended answers (Additional file 1). Responses were
grouped to establish points of consistency and contrast
among expert centres. Topics included MDM organisa-
tion and structure, constitution, diagnostic methodology
and information provided to referring physicians.
Results
After an initial request and one reminder 5 days later,
responses were received from ten out of twelve expert
ILD centres (83 %). Centres were located in Australia,
the USA, Canada, the United Kingdom and France.
Organisation and structure
All centres had dedicated ILD MDMs with most centres
meeting once every 1–2 weeks (90 %). All but 1 centre
discussed six or more cases per meeting, with 4 centres
discussing greater than 10 cases per meeting. The me-
dian duration of the meetings was 31 to 60 min although
3 centres had meetings greater than 90 min.
All MDMs were attended by thoracic clinicians, ra-
diologists and pathologists, and these members con-
tributed most to the MDM. In most centres (90 %),
the MDM was also attended by junior staff and many had
nursing staff present (80 %), with variable contribution
from these groups. In a minority of MDMs, there was
attendance by rheumatologists (30 %), thoracic sur-
geons (20 %) and transplant physicians (30 %). When
present, rheumatology and palliative care physicians
contributed always or frequently to the MDM discus-
sion (Table 1).
Governance
Heterogeneity in the extent and format of information
presented at the ILD MDMs was apparent. In 60 % of
ILD MDMs, only select clinical and investigation find-
ings that were thought to be relevant by the referring
team were presented. The remaining 40 % of meetings
presented all findings and 30 % of meetings used a uni-
form template as the basis for presentation. 60 % pre-
sented clinical data in an audiovisual presentation and
the remaining 40 % used only an oral summary. All cen-
tres required a high resolution CT chest and pulmonary
function tests and most required a surgical lung biopsy
(if performed) (90 %) and rheumatologic serology
(80 %). Six minute walk test and echocardiography was
required in 40 and 30 % of MDMs respectively (Fig. 1).
Thoracic physicians adopted the dominant role in
MDM. In 90 % of meetings, discussion was led by thor-
acic physicians, and 100 % of respondents reported that
physicians were the accountable craft group for the diag-
nosis once it had been made. The referring physician
often had a major role in the MDM. In 70 %, the refer-
ring physician was responsible for documenting the
diagnosis, and in 60 % the referring physician had the
greatest role in formulating the diagnosis. The govern-
ance of diagnostic dilemmas varied between institutions.
While in 60 % of MDMs, a consensus approach to diag-
nosis was used, in 30 % the final decision was left to the
clinician responsible for the case. In one centre, the final
diagnosis was made by the chair of the MDM. Table 2
displays the commonest diagnostic dilemmas facing
expert MDMs.





Thoracic clinician 100 % 100 %
Radiologist 100 % 90 % 10 %
Histopathologist 100 % 100 %
Trainees 90 % 67 %
Nursing staff 80 % 36 %
Rheumatologist 30 % 33 % 67 %
Transplant physician 30 % 33 % 33 %
Thoracic surgeon 20 % 33 %
Immunologist 10 %
Palliative care 10 % 100 %
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Information generated
All MDMs delivered a diagnosis and differentials with
80 % also including a degree of diagnostic confidence. A
minority of MDMs also included a prediction of disease
behaviour (30 %). ILD MDMs generated management
recommendations and treatment aims in 80 and 60 % of
MDMs respectively. Responses are categorized in Table 3
according to their degree of heterogeneity.
Discussion
Our survey has shown that significant heterogeneity ex-
ists in MDM constitution, governance, data input, diag-
nostic process and information provision. The impact of
these differences is unclear, but potentially of crucial im-
portance were it to lead to inaccuracy in disease recogni-
tion and resulting therapeutic choices. Also, as MDM
diagnosis becomes the clinical benchmark, with access
to medications restricted by MDM diagnosis, it is
important that we recognise the limitations of the
MDM and highlight methods to improve consistency
and accuracy.
No randomised trial has ever been performed, or is
ever likely to be, that demonstrates MDM based
diagnosis results in improved patient survival. Its utility
is instead based on the “linked evidence approach” [11]
whereby benefit is derived through improved diagnostic
accuracy and consequent alterations in therapeutic ap-
proach. It is clear that there is an increasing range of
therapeutic choices for ILD, including anti-fibrotic ther-
apy for IPF [4, 5], antigen avoidance for chronic hyper-
sensitivity pneumonitis [12, 13], immune suppression for
inflammatory and connective tissue disease related dis-
ease [14–20], lung transplantation [21] and palliative ap-
proaches [7]. Many of those therapies have robust
evidence for their benefit when applied to specific diag-
noses, such as the anti-fibrotic therapies nintedanib and
pirfenidone [4, 5] which are now recommended therap-
ies in the revised IPF consensus statement [22, 23].
Given the established evidence for MDM’s association
with improved diagnostic accuracy [2, 6, 24], our finding
that MDMs are a ubiquitous feature among the expert
centres surveyed in our study is not a surprising finding.
Despite the clear utility and importance of ILD
MDMs, the constitution and governance of these meet-
ings has never been explored or addressed. Our survey
shows that expert centres’ MDM demonstrate several
points of consistency in their meetings, being consti-
tuted at a minimum by thoracic physicians, radiologists
and pathologists - although contribution from non-
thoracic clinicians varied - and considering a similar set
of clinical and investigative data. However, within this
range of broad similarity, significant heterogeneity was
seen in MDM governance. This was apparent in the ex-
tent of information provided, the presentation style and
the approach to resolution of diagnostic dilemmas,
which varied between a consensus approach and deferral
to the clinician responsible for the case. While the ef-
fects of such heterogeneity amongst ILD MDMs are not
clear, it could be hypothesised that those with less infor-
mation presented and less group input with regard to
final diagnosis would behave little differently to an
individual clinician. Further research that explores the
effects of such heterogeneity on MDM diagnostic per-
formance, considers MDM models that provide the most
accuracy and concordance, validates the utility of MDM
versus other models of diagnosis, and longitudinally
explores outcomes, is of paramount importance if MDM
is to adequately perform a role as a final arbiter of
diagnosis.
Our survey also demonstrated that the majority of
MDMs generate outputs in addition to diagnosis, includ-
ing management recommendations and treatment aims.
Interestingly, while multi-craft group meetings focused
both on diagnosis and management are the norm in the
treatment of other pulmonary conditions such as lung
cancer, in only a minority of ILD MDMs did other craft
















Fig. 1 Minimum requisite investigations presented at ILD MDMs






IPF diagnosis, classification and differentiation
from other ILDs
8 6
Recognition of chronic HP 6 5
Recognition of non-IPF ILD’s: CTD-ILD, CPFE,
cystic lung disease, NSIP
9 4
Interpretation of poorly classifiable findings 4 0
Interpretation of poor quality diagnostic material 2 0
Management decisions
Need for biopsy 2 0
Whether to recommend immune-suppression 3 0
Whether to recommend anti-fibrotic therapy 2 0
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additional outputs. This is despite the fact that many
ILD diagnoses have co-morbidities, and produce signifi-
cant impairment and mortality, such that the meeting
may provide an excellent opportunity for referral to rele-
vant craft groups, such as transplant [21] and palliative
care services [7]. The utility of non pulmonary craft
group attendees was highlighted in our survey by
rheumatology attendees, who contribute frequently or
always to discussion in 100 % of meetings they attended.
Clearly, local regulatory and insurer factors will have
significant impact on the frequency and nature of the
use of MDM in the management of ILD, and any pos-
ition statement would need to be tailored to reflect re-
gional circumstances. For those regions where MDM is
used, we propose a set of core criteria for structure and
governance, given our survey’s findings with regards to
heterogeneity and the implied impact this may have on
diagnosis and subsequent therapeutic recommendation.
These are likely to include the features listed in Table 4,
which were common to the majority of centres surveyed.
A number of other features, including the attendance
and influence of other specialties, presentation format,
and data outputs other than a diagnosis, were not
uniform, and thus are difficult to ascribe as core fea-
tures. However, in developing any expert statement, we
suggest such features be considered and guidance given
as to which additional features to core criteria are pre-
ferred, particularly those that might decrease potential
bias and increase the utility of the ILD MDM.
An important area our study did not explore is the
prescription patterns for those patients undergoing diag-
nosis via heterogeneous MDMs. Our study focused
solely on expert centres, but it is impractical to imagine
that in most regions there are sufficient expert centres
present to provide similarly constituted MDM. It is
therefore inevitable that heterogeneity will exist in
MDM with regards to expertise, based on whether they
are located in community or academic centres. Aca-
demic MDMs when compared to community centres
have previously been demonstrated to possess different
diagnostic performance, with an increased likelihood of
alternative diagnoses to IPF and therefore by corollary, a
probable decreased frequency of prescription of anti-
fibrotic therapy [9]. A further contributor to such differ-
ences in prescription rates may be via regional differ-
ences in approaches taken by regulatory authorities to
anti-fibrotic therapy prescription and whether or not the
MDM has been specifically mandated to control the pre-
scription of anti-fibrotics. Each of these potentially has
fundamental health economic implications, with regards
the frequency of prescription of anti-fibrotic therapies.
A perceived limitation of our study is its concentration
solely on expert centres. These centres however, were
deliberately chosen in the belief they would most likely
have a common approach to ILD diagnosis and manage-
ment. Despite being a small and highly selected sample,
the centres demonstrated significant heterogeneity. A
wider survey of non-academic centres to determine
whether even broader heterogeneity in MDM output oc-
curs would be worthwhile. Also, we did not explore any
Table 3 Differences in surveyed Multidisciplinary meetings (MDM)






Attendance by thoracic physician, radiologist,




Attendance by rheumatologist, immunologist,
transplant physician, thoracic surgeon.
Governance
Performance of HRCT, PFT, lung biopsy,
rheumatological serology.
MDM lead by thoracic physician
Use of audiovisual presentation vs
oral presentation only
Presentation of relevant vs all clinical findings.







Final diagnosis made by consensus vs clinician
responsible for case
Table 4 Core criteria for interstitial lung disease multidisciplinary
meetings
1. An adequate case-load to enable a frequency of meetings
commensurate with the development and maintenance of expertise
in ILD diagnosis;
2. Attendance by at least one respiratory physician, radiologist and
histopathologist;
3. Data presentation by the clinician directly responsible for the
patient’s care;
4. Presentation of a set of routine investigations that include high
quality HRCT images, PFT, rheumatological serology and, if available,
histology;
6. A consensus approach to diagnosis formulation;
7. The provision of a diagnosis, degree of diagnostic confidence,
and differential diagnoses.
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specific patient outcomes but instead inferred using
existing literature that heterogeneity in ILD MDMs
would likely result in a significant difference in ILD
MDM diagnostic performance [6, 9, 24–28]. This hypoth-
esis requires confirmation in further studies that explore
differences in diagnosis and treatment recommendations.
Conclusion
We have demonstrated that ILD MDMs in expert cen-
tres differ considerably in their organization and struc-
ture, governance and information generated. While ILD
MDMs are the “gold standard” for diagnosis, there are
limited data on the impact that heterogeneity in MDMs
has on diagnostic and management outputs. There are
indications that meeting format and the expertise of
attendees alters diagnostic agreement but further re-
search to clarify the concordance between heteroge-
neous MDMs using current diagnostic guidelines is
required. As ILD MDMs become increasingly frequent
and produce additional outputs, there is a need for
evidence based clinical guidelines regarding their consti-
tution and governance to ensure the best clinical out-
comes in these frequently devastating diseases.
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